|
KaloBios to Stop KB003 Development for Asthma – Analyst Blog
NASDAQ KaloBios Pharmaceuticals, Inc. ( KBIO ) announced disappointing top line results from a phase II study on KB003 in patients suffering from severe asthma, where the candidate failed to meet the key endpoints. We expect the news to have a significant … KaloBios shares tank on failed asthma drug trial KaloBios calls it quits on its asthma drug after a Phase II flop KaloBios Pharma pulls plug on asthma drug, shares plunge |
View full post on asthma – Google News